Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANNX 
Annexon Inc (ANNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ANNX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.6
1 Year Target Price $11.6
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.75% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 307.20M USD | Price to earnings Ratio - | 1Y Target Price 11.6 |
Price to earnings Ratio - | 1Y Target Price 11.6 | ||
Volume (30-day avg) 8 | Beta 1.26 | 52 Weeks Range 1.28 - 7.85 | Updated Date 07/12/2025 |
52 Weeks Range 1.28 - 7.85 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.66% | Return on Equity (TTM) -66.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47675162 | Price to Sales(TTM) - |
Enterprise Value 47675162 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.47 | Shares Outstanding 109714000 | Shares Floating 82380157 |
Shares Outstanding 109714000 | Shares Floating 82380157 | ||
Percent Insiders 0.56 | Percent Institutions 102.98 |
Upturn AI SWOT
Annexon Inc
Company Overview
History and Background
Annexon, Inc. is a clinical-stage biopharmaceutical company founded in 2011. It focuses on developing therapies for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic diseases. It went public in 2020. The company's initial focus was on C1q inhibition.
Core Business Areas
- Drug Development: Development of novel therapies targeting the classical complement pathway to treat various diseases, including Guillain-Barru00e9 syndrome (GBS), Huntington's disease (HD), and geographic atrophy (GA).
Leadership and Structure
The leadership team includes Douglas Love, President and CEO. The organizational structure is typical for a biotech company, with departments focused on research, development, clinical trials, and operations.
Top Products and Market Share
Key Offerings
- ANX005 (IV): Intravenous formulation currently in clinical trials for autoimmune diseases like Guillain-Barru00e9 syndrome (GBS). No current market share data available as it is still in development. Competitors depend on the specific indication, for GBS, intravenous immunoglobulin (IVIg) is a primary competitor.
- ANX005 (Subcutaneous): Subcutaneous formulation being developed for chronic neurodegenerative diseases, such as Huntington's Disease. No market share data available as it is in clinical trials. Primary competitors include therapies managing the symptoms of Huntington's, with no specific disease-modifying treatments currently available. Potential future competitors include gene-editing therapies targeting the underlying cause of HD.
- ANX007: An antigen-binding fragment (Fab) designed for ophthalmic indications like geographic atrophy (GA). No market share data available as it is in clinical trials. Iveric Bio's IZERVAY (avacincaptad pegol) and Apellis' SYFOVRE (pegcetacoplan) are direct competitors in the GA space.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The complement therapeutics market is growing due to increased understanding of the complement system's role in various diseases.
Positioning
Annexon is positioned as an innovator in complement-mediated disease therapies, focusing on inhibiting C1q, the initiating molecule of the classical complement pathway. Its competitive advantage lies in its targeted approach and potential to address unmet needs in autoimmune, neurodegenerative, and ophthalmic indications.
Total Addressable Market (TAM)
The TAM for complement-mediated therapies is substantial, potentially reaching billions of dollars across the various indications Annexon is targeting (GBS, HD, GA). Annexon is positioned to capture a significant portion of this TAM if its clinical trials are successful and its therapies are approved.
Upturn SWOT Analysis
Strengths
- Novel approach to complement inhibition
- Diverse pipeline targeting multiple indications
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical trial risks and uncertainties
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Positive clinical trial results could lead to rapid market adoption
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion into new indications
- Orphan drug designations and regulatory advantages
Threats
- Competition from other companies developing complement inhibitors
- Regulatory hurdles and delays
- Unfavorable clinical trial results
- Patent challenges
Competitors and Market Share
Key Competitors
- APLS
- IVERIC Bio
Competitive Landscape
Annexon competes with companies developing therapies targeting the complement system and those offering treatments for the specific indications they are pursuing. Annexon's advantage may be in its specific approach to C1q inhibition, but it faces significant competition from larger, more established companies. Note that Annexon has not yet launched a product on the market and has therefore has zero percent of current market share.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily based on pipeline progress and expansion of clinical programs. The company has grown its pipeline and advanced its programs through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary depending on pipeline advancement. Revenue is projected upon drug approval.
Recent Initiatives: Recent initiatives include advancing clinical trials for ANX005 (IV), ANX005 (subcutaneous), and ANX007, and presenting data at scientific conferences.
Summary
Annexon is a clinical-stage biopharmaceutical company with a promising pipeline focused on complement inhibition. The company's future hinges on the successful completion of its clinical trials and regulatory approvals. Its C1q inhibition approach has the potential to disrupt several disease areas. Investors should carefully monitor clinical trial results and cash reserves, as the company is not yet profitable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annexon Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2020-07-24 | CEO, President & Director Mr. Douglas E. Love Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.annexonbio.com |
Full time employees 106 | Website https://www.annexonbio.com | ||
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.